Site 14 - CCP - Pittsburgh Pediatrics 6000 Brooktree Road Suite 207 — Wexford, Pennsylvania

Site 14 - CCP - Pittsburgh Pediatrics 6000 Brooktree Road Suite 207 is a clinical research site located in Wexford, Pennsylvania, United States 15090.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Site 14 - CCP - Pittsburgh Pediatrics 6000 Brooktree Road Suite 207 has participated in 1 clinical trials.

Therapeutic areas: Meningococcal Infections.

Sponsors: Novartis Vaccines.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Wexford

Browse all research sites in Pennsylvania · View every site in Wexford

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site 14 - CCP - Pittsburgh Pediatrics 6000 Brooktree Road Suite 207?

Site 14 - CCP - Pittsburgh Pediatrics 6000 Brooktree Road Suite 207 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site 14 - CCP - Pittsburgh Pediatrics 6000 Brooktree Road Suite 207 conducted?

Site 14 - CCP - Pittsburgh Pediatrics 6000 Brooktree Road Suite 207 has 1 clinical trials on record. Their work covers Meningococcal Infections.

Is Site 14 - CCP - Pittsburgh Pediatrics 6000 Brooktree Road Suite 207 accredited by Crixeo Clinical Trials?

Site 14 - CCP - Pittsburgh Pediatrics 6000 Brooktree Road Suite 207 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site 14 - CCP - Pittsburgh Pediatrics 6000 Brooktree Road Suite 207?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.